| Literature DB >> 29237759 |
Peter Abbink1, Rafael A Larocca1, Kittipos Visitsunthorn1, Michael Boyd1, Rafael A De La Barrera2, Gregory D Gromowski2, Marinela Kirilova1, Rebecca Peterson1, Zhenfeng Li1, Ovini Nanayakkara1, Ramya Nityanandam1, Noe B Mercado1, Erica N Borducchi1, Abishek Chandrashekar1, David Jetton1, Shanell Mojta1, Priya Gandhi1, Jake LeSuer1, Shreeya Khatiwada1, Mark G Lewis3, Kayvon Modjarrad2, Richard G Jarman2, Kenneth H Eckels2, Stephen J Thomas2, Nelson L Michael2, Dan H Barouch4,5.
Abstract
An effective Zika virus (ZIKV) vaccine will require long-term durable protection. Several ZIKV vaccine candidates have demonstrated protective efficacy in nonhuman primates, but these studies have typically involved ZIKV challenge shortly after vaccination at peak immunity. We show that a single immunization with an adenovirus vector-based vaccine, as well as two immunizations with a purified inactivated virus vaccine, afforded robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination. In contrast, two immunizations with an optimized DNA vaccine, which provided complete protection at peak immunity, resulted in reduced protective efficacy at 1 year that was associated with declining neutralizing antibody titers to subprotective levels. These data define a microneutralization log titer of 2.0 to 2.1 as the threshold required for durable protection against ZIKV challenge in this model. Moreover, our findings demonstrate that protection against ZIKV challenge in rhesus monkeys is possible for at least 1 year with a single-shot vaccine.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29237759 PMCID： PMC5747972 DOI： 10.1126/scitranslmed.aao4163
Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956